CD8A and neoplasm: To confirm that we can elicit responses to other relevant tumor antigens, we processed mouse RBCs with a synthetic long peptide (SLP) containing the minimal epitope for the HPV16 viral oncoprotein E7 (Supplementary Table S1) in the presence of poly I:C and assessed CD8+ T cell responses 7-days following AAC-E7 administration (15, 50–52).